IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: The tryptophan-catabolizing enzyme IDO1 and its metabolite kynurenine were shown to be enhanced in patients with chronic lymphocytic leukemia (CLL), and their involvement in T cell suppression and immune escape was suggested. As we have observed increased IDO1 expression and kynureni...

Descripción completa

Detalles Bibliográficos
Autores principales: Öztürk, Selcen, Kalter, Verena, Roessner, Philipp M., Sunbul, Murat, Seiffert, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071295/
https://www.ncbi.nlm.nih.gov/pubmed/33920868
http://dx.doi.org/10.3390/cancers13081899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071295/
https://www.ncbi.nlm.nih.gov/pubmed/33920868
http://dx.doi.org/10.3390/cancers13081899

Ejemplares similares